


## sEH inhibitor-16

<b>Cat. No.:</b>	HY-155029
<b>CAS No.:</b>	2999636-75-6
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>37</sub> N <sub>3</sub> O
<b>Molecular Weight:</b>	455.63
<b>Target:</b>	Epoxide Hydrolase
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitors with an IC <sub>50</sub> of 2 nM. sEH inhibitor-16 reduces the inflammatory damage in Cerulein (A0190)-induced acute pancreatitis (AP) in mice and can be used for inflammation/immunology research <sup>[1]</sup> .					
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 2 nM (sEH) <sup>[1]</sup>					
<b>In Vivo</b>	sEH inhibitor-16 (Compound 28) (10 mg/kg for i.p.) displays protective effects in mouse Cerulein (HY-A0190)-induced acute pancreatitis <sup>[1]</sup> . sEH inhibitor-16 (Compound 28) (10 mg/kg for i.p.) shows an T <sub>1/2</sub> of 7.6 hours and a C <sub>max</sub> of 4.17 ng/mL in CD-1 mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.					
<b>Animal Model:</b>	The murine model of AP induced by repeated Cerulein (HY-A0190) injections <sup>[1]</sup>					
<b>Dosage:</b>	10mg/kg					
<b>Administration:</b>	Intraperitoneal injection (i.p.)					
<b>Result:</b>	Displayed a protective effect evidenced by the reduction of edema, cell infiltration, and neutrophil numbers.					
<b>Animal Model:</b>	Male CD-1 mice (Pharmacokinetic assay) <sup>[1]</sup>					
<b>Dosage:</b>	10mg/kg					
<b>Administration:</b>	Intraperitoneal injection (i.p.)					
<b>Result:</b>	Pharmacokinetic parameters for sEH inhibitor-16 (Compound 28) in CD-1 mice <sup>[1]</sup>					
	Route	Dose (mg/kg)	T <sub>1/2</sub> (h)	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)	AUC <sub>0-∞</sub> (h•ng/mL)
	i.p.	10	7.6	2	4.17	29.9

---

## REFERENCES

[1]. Musella S, et.al. Design, Synthesis, and Pharmacological Characterization of a Potent Soluble Epoxide Hydrolase Inhibitor for the Treatment of Acute Pancreatitis. *J. Pharm. Med. Clin. Oncol.* 2023 Jul 13;66(13):9201-9222.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA